




Supplementary Figure S4. In silico Paclitaxel Drug Sensitivity Test comparing the subtypes

(a) Preoperative (radical prostatectomy, RP) serum PSA levels presented in box plot (5%–95%, upper) and stacked bar chart (class interval: 10 ng/mL, 20 ng/mL, lower). Multiple comparison assessed by Kruskal-Wallis test. (b) Luminal A and luminal S subtypes preoperative serum PSA levels, stratified by pT stage. Multiple t-test, Holm-Sidak method, without assuming a consistent standard deviation. (c) Serum PSA levels of luminal A and AVPC-I subtypes from the SU2C-PCF 2019 dataset. P value by Mann-Whitney test. (d) KLK3 and ACP3 mRNA expression levels of luminal A and AVPC-M subtypes from the SU2C-PCF mCRPC dataset. (e) KLK3 and ACP3 mRNA expression levels of metastatic tissues from mCRPC patients receiving enzalutamide. Samples divided into responders and nonresponders by PSA50 response (PSA decline of $\geq 50\%$ at 12 wk compared with baseline) RNA-Seq data from Alumkal et al. (Alumkal et al., PNAS, 2020). (f) Scatter plot of two prostatic acid phosphatase (A.P.) test result values measured simultaneously in samples of prostate cancer patients of Severance Hospital from Jan 2006 to July 2020. Line = Linear Regression Analysis. (g) Serum PSA/PAP ratio changes before and during goserelin injection in docetaxel-prednisone chemotherapy in mCRPC patients.